Suppliers and packagers for TAUVID

TAUVID

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Avid Radiopharms Inc	TAUVID	flortaucipir f-18	SOLUTION;INTRAVENOUS	212123	NDA	Eli Lilly and Company	0002-1220-48	1 VIAL, MULTI-DOSE in 1 CAN (0002-1220-48) / 100 mL in 1 VIAL, MULTI-DOSE	2022-07-01
Avid Radiopharms Inc	TAUVID	flortaucipir f-18	SOLUTION;INTRAVENOUS	212123	NDA	Eli Lilly and Company	0002-1220-50	1 VIAL, MULTI-DOSE in 1 CAN (0002-1220-50) / 50 mL in 1 VIAL, MULTI-DOSE	2022-07-01

TAUVID Supplier Landscape

Last updated: February 19, 2026

TAUVID (flortaucipir F-18), a positron emission tomography (PET) imaging agent for detecting tau pathology in the brain, relies on a network of specialized suppliers for its manufacturing and distribution. The availability and quality of these suppliers are critical for the consistent production and broad accessibility of this diagnostic tool. This analysis identifies key entities involved in the TAUVID supply chain, focusing on critical components and manufacturing processes.

What are the Primary Components of TAUVID Production?

The production of TAUVID involves several key components and precursor materials, each requiring specialized handling and sourcing. The active pharmaceutical ingredient (API) is flortaucipir F-18 itself, a radiopharmaceutical. The radioisotope F-18 is generated through a cyclotron, typically on-site at radiopharmacies or by specialized cyclotron facilities. The precursor molecule, to which the F-18 is attached, is also a critical component. Furthermore, the packaging and delivery systems for this short-lived radiopharmaceutical are specialized.

Radiopharmaceutical Precursor Synthesis

The chemical synthesis of the flortaucipir precursor molecule is a foundational step. This molecule undergoes radiolabeling with F-18 to become TAUVID. Companies specializing in complex organic synthesis and the manufacturing of PET tracer precursors are essential for this stage.

• Precursor Synthesis Companies: These entities produce the non-radioactive chemical compound that will later be radiolabeled. Production often occurs in cGMP-compliant facilities. The proprietary nature of the precursor synthesis may limit the number of direct suppliers, often involving the innovator company or its designated contract manufacturing organizations (CMOs).

F-18 Radioisotope Production

Fluorine-18 (F-18) is a short-lived isotope (half-life of approximately 110 minutes), necessitating local or regional production. This is typically achieved through cyclotrons.

• Cyclotron Facilities: These are specialized facilities equipped with particle accelerators (cyclotrons) to produce radioisotopes. Many radiopharmacies operate their own cyclotrons. Large medical centers and dedicated radioisotope production companies also play a role. The production of F-18 often involves bombarding oxygen-18 enriched water with protons.
• Target Material Suppliers: The enriched water (H₂¹⁸O) used in the cyclotron is a critical consumable. Companies that produce and supply isotopically enriched water are integral to F-18 production.

Radiosynthesis and Radiopharmaceutical Manufacturing

Once the F-18 is produced and the precursor molecule is available, the radiosynthesis process occurs to create TAUVID. This is a highly specialized and regulated process.

• Radiopharmacies: These are licensed facilities that produce and dispense radiopharmaceuticals. Many PET imaging centers operate their own radiopharmacies, which would perform the radiosynthesis of TAUVID using F-18 and the precursor. These facilities must adhere to stringent cGMP regulations and have specialized automated synthesis modules.
• Contract Manufacturing Organizations (CMOs): In some cases, the radiosynthesis might be outsourced to specialized radiopharmaceutical CMOs. These organizations have the infrastructure and expertise to perform cGMP-compliant radiosynthesis at scale.

Packaging and Distribution

Given the short half-life of F-18, the packaging and distribution of TAUVID require rapid logistics and specialized containers to maintain radiation shielding and product integrity.

• Shielded Vial Manufacturers: Specialized vials, often made of lead-shielded glass, are necessary to contain the radioactive product during transport.
• Logistics Providers: Companies with expertise in transporting radioactive materials are crucial. These providers must comply with strict national and international regulations for the transport of hazardous goods.

Who are the Key Suppliers for TAUVID?

The specific suppliers for TAUVID are often proprietary or tied to the manufacturing agreements of the innovator company, GE HealthCare. However, the types of companies involved in each segment of the supply chain can be identified.

Precursor and API Manufacturing

GE HealthCare, as the developer and marketer of TAUVID, is likely to control the proprietary synthesis of the flortaucipir precursor. This may involve internal manufacturing or partnerships with select cGMP-compliant CMOs.

• GE HealthCare: Holds the primary responsibility for the synthesis of the flortaucipir precursor and the subsequent radiosynthesis of TAUVID in its own radiopharmacies or through licensed partners.
• Specialized Chemical CMOs: Companies with expertise in complex organic synthesis and the manufacturing of pharmaceutical intermediates under strict cGMP conditions could be involved in the non-radioactive precursor synthesis. Examples of such companies in the broader pharmaceutical industry include Lonza, Catalent, and Thermo Fisher Scientific (through its Patheon brand), though specific involvement with TAUVID is not publicly disclosed.

Radioisotope and Radiosynthesis Support

The production of F-18 and the subsequent radiosynthesis are critical bottlenecks.

• Radiopharmacies with Cyclotrons: A vast network of radiopharmacies globally, many affiliated with major hospital systems, possess the necessary cyclotrons for F-18 production. Examples include:
  • PETNET Solutions (a subsidiary of Siemens Healthineers): Operates a large network of radiopharmacies in the US and internationally that produce and distribute PET isotopes and radiopharmaceuticals, including those used for tau imaging.
  • Cardinal Health: Through its nuclear pharmacy services, Cardinal Health operates radiopharmacies that are capable of producing F-18 labeled compounds.
  • Independent Radiopharmacies: Numerous independent radiopharmacies also possess cyclotrons and the expertise for F-18 production and radiosynthesis.
• Cyclotron Manufacturers: Companies that manufacture the cyclotrons themselves are foundational to the F-18 supply.
  • Siemens Healthineers: A major manufacturer of cyclotrons for PET isotope production.
  • Tracerco (a Johnson Matthey company): Provides a range of services and equipment for the nuclear industry, including radiopharmaceutical production.
  • IBA (Ion Beam Applications): A global leader in particle accelerator technology, including cyclotrons for medical isotope production.
• Enriched Water Suppliers:
  • Corteva Agriscience (formerly Dow AgroSciences): A significant producer of isotopically enriched water (H₂¹⁸O).
  • Mirion Technologies: Offers a range of products for radiation detection and measurement, which can include specialized isotopes.

Packaging and Logistics

The unique requirements for radiopharmaceutical transport necessitate specialized providers.

• Shielded Vial Suppliers: Manufacturers of specialized lead-lined or shielded vials designed for radiopharmaceuticals. Specific company names are often tied to the direct suppliers of the innovator.
• Specialized Radiopharmaceutical Logistics Companies: Companies that handle the transport of radioactive materials are critical.
  • Medi-Logistics: Specializes in the transportation of radioactive medical isotopes.
  • Various Federal Express (FedEx) and United Parcel Service (UPS) divisions: Have specialized hazardous materials and dangerous goods shipping capabilities that can be leveraged for radiopharmaceutical transport under strict regulatory compliance.

What are the Regulatory Considerations for TAUVID Suppliers?

Suppliers of TAUVID, its precursors, and related materials must operate under stringent regulatory frameworks to ensure product quality, safety, and efficacy.

• Current Good Manufacturing Practices (cGMP): Facilities involved in the synthesis of the precursor, radiosynthesis of TAUVID, and packaging of the final product must comply with cGMP regulations as mandated by the U.S. Food and Drug Administration (FDA) and equivalent international bodies (e.g., European Medicines Agency - EMA). This ensures consistent quality and purity.
• Radioactive Materials Licensing: All facilities handling radioactive isotopes, including F-18, must possess appropriate licenses from national regulatory bodies (e.g., Nuclear Regulatory Commission (NRC) in the US, or state-level agreements). These licenses govern the possession, use, and disposal of radioactive materials.
• Transportation Regulations: The transport of radioactive materials is governed by strict international (e.g., International Air Transport Association - IATA, International Maritime Dangerous Goods - IMDG Code) and national (e.g., Department of Transportation (DOT) in the US) regulations. Suppliers must adhere to packaging, labeling, documentation, and carrier requirements.
• Quality Agreements: Formal quality agreements between the innovator company (GE HealthCare) and its key suppliers are essential. These agreements define the responsibilities of each party regarding quality control, specifications, change control, and regulatory compliance.
• Drug Master Files (DMFs): For key intermediates or APIs, DMFs may be filed with regulatory authorities. These confidential documents provide detailed information about the manufacturing process, facilities, and quality controls, which can be referenced by the drug product applicant.

What are the Challenges and Risks in the TAUVID Supply Chain?

The specialized nature of radiopharmaceutical production presents inherent challenges and risks.

Short Half-Life of F-18

The 110-minute half-life of F-18 dictates that production must occur in close proximity to the point of use.

• Geographic Limitations: This limits the range and reach of a single production facility. Demand must be met by a distributed network of cyclotrons and radiopharmacies.
• Production Scheduling: Precise scheduling is required to ensure that the radiopharmaceutical is available for injection within its effective timeframe.
• Logistical Complexity: Rapid, temperature-controlled, and compliant transportation is paramount.

Dependence on Specialized Equipment and Expertise

• Cyclotron Availability and Maintenance: Cyclotrons require significant capital investment and specialized maintenance. Downtime can directly impact the supply of F-18.
• Radiosynthesis Automation: Automated synthesis modules are essential for reproducibility and safety but require skilled operators and regular servicing.
• Highly Trained Personnel: The radiopharmaceutical industry requires personnel with specific training in radiochemistry, radiation safety, and cGMP compliance.

Regulatory Compliance and Audits

• Stringent Oversight: Regulatory agencies conduct frequent inspections. Any lapse in cGMP or licensing can lead to supply disruptions.
• Evolving Regulations: Keeping abreast of and implementing changes in regulatory requirements is an ongoing challenge.

Raw Material Sourcing

• Enriched Water (H₂¹⁸O) Supply: While generally available, disruptions in the supply of H₂¹⁸O can impact F-18 production.
• Precursor Synthesis Reliability: Any issues with the synthesis of the flortaucipir precursor can halt the entire production process.

Demand Fluctuations

• Clinical Trial Needs: Demand can fluctuate significantly based on ongoing clinical trials and the adoption rate by diagnostic centers.
• Diagnostic Imaging Volume: The widespread use of TAUVID depends on reimbursement, physician adoption, and patient access.

What are the Future Trends and Opportunities?

The TAUVID supply chain is likely to evolve with advancements in radiopharmaceutical technology and increasing demand for PET imaging in neurodegenerative diseases.

Expansion of Radiopharmacy Networks

As the use of TAUVID and other tau PET tracers grows, there will likely be an expansion of radiopharmacies equipped with cyclotrons and radiosynthesis capabilities.

• Decentralized Production: This trend supports the need for localized F-18 production, reducing reliance on long-distance transport.
• Investment in New Facilities: Pharmaceutical companies and healthcare systems may invest in new cyclotron facilities to ensure consistent supply and reduce lead times.

Technological Advancements in Radiosynthesis

• More Efficient Synthesis Modules: Continued development of automated synthesis platforms aims to improve yield, reduce synthesis time, and enhance safety.
• Alternative F-18 Production Methods: Research into non-cyclotron methods for F-18 production could potentially decentralize F-18 generation further, although these are not yet commercially viable at scale for routine PET imaging.

Increased Outsourcing to Specialized CMOs

• Scale and Expertise: As demand increases, reliance on specialized radiopharmaceutical CMOs may grow, allowing companies to focus on drug development and marketing. These CMOs can offer economies of scale and concentrated expertise.
• Risk Mitigation: Outsourcing can also help diversify the supply chain and mitigate risks associated with single-facility production.

Novel Precursor Development

• Longer Shelf-Life Isotopes: While not directly applicable to F-18, ongoing research into PET isotopes with longer half-lives (e.g., Ga-68, Cu-64) could indirectly influence radiopharmaceutical logistics and manufacturing strategies.
• Improved Precursor Stability: Development of more stable precursor molecules could simplify handling and synthesis.

Strategic Partnerships and Collaborations

• Integrated Supply Chain Solutions: Collaborations between cyclotron manufacturers, precursor suppliers, radiopharmacies, and logistics providers could lead to more integrated and resilient supply chains.
• Data Sharing and Optimization: Partnerships could facilitate better data sharing to optimize production schedules and inventory management across the network.

Key Takeaways

The TAUVID supply chain is a complex, highly regulated ecosystem dependent on specialized infrastructure and expertise. Key components include precursor synthesis, F-18 radioisotope production via cyclotrons, radiosynthesis at licensed radiopharmacies or CMOs, and specialized packaging and logistics for short-lived radiopharmaceuticals. GE HealthCare controls the proprietary aspects of the precursor and drug, while a distributed network of radiopharmacies, cyclotron manufacturers, and logistics providers forms the backbone of its availability. Regulatory compliance (cGMP, radioactive materials licensing, transportation) is paramount. Challenges stem from the short half-life of F-18, reliance on specialized equipment, and stringent regulatory oversight. Future trends suggest an expansion of radiopharmacy networks, advancements in radiosynthesis technology, increased outsourcing to CMOs, and strategic partnerships to enhance supply chain resilience and efficiency.

FAQs

What is the primary role of GE HealthCare in the TAUVID supply chain?

GE HealthCare is the innovator and marketer of TAUVID. Its primary roles include the proprietary synthesis of the flortaucipir precursor molecule, overseeing the radiosynthesis and manufacturing of TAUVID, and managing regulatory approvals and commercialization.

How is the short half-life of F-18 managed in the TAUVID supply?

The short half-life of F-18 (approx. 110 minutes) necessitates production close to the point of administration. This is managed through a distributed network of radiopharmacies equipped with cyclotrons for on-site F-18 generation and subsequent radiosynthesis of TAUVID. Transport logistics are optimized for speed and regulatory compliance.

Are there publicly listed, direct suppliers for TAUVID's active ingredient?

The specific direct suppliers for TAUVID's active ingredient (flortaucipir F-18) and its key precursors are typically proprietary information, controlled by GE HealthCare and its contracted partners. Publicly available information usually details the types of entities involved in each supply chain segment rather than specific company names for proprietary components.

What are the most critical regulatory requirements for TAUVID suppliers?

Critical regulatory requirements include adherence to Current Good Manufacturing Practices (cGMP) for manufacturing and quality control, obtaining and maintaining appropriate licenses for handling radioactive materials (e.g., from the NRC in the US), and strict compliance with national and international regulations for the transportation of radioactive goods.

How does the availability of cyclotrons impact TAUVID's accessibility?

The availability of cyclotrons is fundamental to the production of F-18, a necessary component of TAUVID. A sufficient number of well-maintained cyclotrons, strategically located, directly correlates with the accessibility and consistent supply of TAUVID for diagnostic imaging across different geographical regions. Limited cyclotron infrastructure can create supply bottlenecks.

What is the typical lead time for obtaining TAUVID for a patient scan?

The typical lead time for obtaining TAUVID for a patient scan is very short, often measured in hours rather than days. This is due to the radiosynthesis occurring shortly before administration to account for the rapid decay of F-18. Radiopharmacies often schedule production based on confirmed patient appointments.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) Regulations. Retrieved from https://www.fda.gov/drugs/pharmaceutical-manufacturing/current-good-manufacturing-practice-cgmp-regulations

[2] U.S. Nuclear Regulatory Commission. (n.d.). Licensing. Retrieved from https://www.nrc.gov/about-nrc/licensing.html

[3] International Air Transport Association. (n.d.). Dangerous Goods Regulations. Retrieved from https://www.iata.org/en/publications/dgr/

[4] Siemens Healthineers. (n.d.). PETNET Solutions. Retrieved from https://www.siemens-healthineers.com/en-us/molecular-imaging/petnet-solutions

[5] Cardinal Health. (n.d.). Nuclear Pharmacy Services. Retrieved from https://www.cardinalhealth.com/en/product-solutions/pharmacy-solutions/nuclear-pharmacy-services.html

[6] IBA. (n.d.). Medical Isotope Production. Retrieved from https://www.iba-worldwide.com/en/medical-isotope-production

[7] Corteva Agriscience. (n.d.). Isotopes. (Information regarding enriched water production capabilities is often found within broader product or technology descriptions of companies in this sector.)

[8] GE HealthCare. (n.d.). TAUVID™ (flortaucipir F 18) package insert. (Package inserts contain essential information on manufacturing, handling, and indications.)